Biosimilar for HER2+ breast cancer achieves similar overall response rate to referenc
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported at the ESMO Asia 2019 Congress.
More... |
All times are GMT -7. The time now is 03:16 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021